From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

Summary

MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls

Eligibility

Inclusion Criteria :

Common criteria for retrospective MS patients:

* Patients aged 18 years or older
* Clinical isolated syndrome (CIS) with or without dissemination in space
* Patients affiliated to an appropriate health insurance

Criteria for Aggressive MS group

• Start of a 2nd line therapy within the two years following the CIS

Criteria for Non aggressive MS group

* No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or
* Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years.
* Have a minimum of least 2 years of follow-up.

Healthy volunteers

* Aged 18 years or older
* No history of clinically isolated syndrome or MS

Pairing criteria :

* Age +/- 5 years
* Sex

Prospective MS Patients

* Patients aged 18 years or older
* Clinical isolated syndrome (CIS) with or without dissemination in space
* Patients affiliated to an appropriate health insurance

Exclusion Criteria :

* Ongoing participation to a another study
* Refusal to genetic analyses
* Immunosuppressive drug at the time of blood collection
* Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample
* Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)
* Pregnancy

Conditions1

Browse More Trials